Table 1 Patient characteristics before the start of ITF2357.
From: Effects of the Histone Deacetylase Inhibitor ITF2357 in Autoinflammatory Syndromes
Patient | Age/sex | Disease | Mutation (gene) | Attack frequency (per month) | Attack duration (days) | Prior medication (mg/day) |
|---|---|---|---|---|---|---|
1 | 24/F | TRAPS | C43Y (TNFRSF1A) | 1.5 | 10–14 | 10 mg prednisolone, anakinra oda |
2 | 64/M | Schnitzler | — | Continuous | — | 25 mg prednisolone |
3 | 61/F | Schnitzler | — | Continuous | — | 100 mg anakinra |
4 | 21/F | HIDS | V377I/V377I (MVK) | 1.5 | 4—8 | Anakinra od |
5 | 61/M | Schnitzler | — | Continuous | — | 100 mg anakinra, 5 mg levocetirizin |
6 | 38/F | HIDS | V377I/G202R (MVK) | 1.0 | 3–6 | — |
7 | 39/F | HIDS | V377I/del (MVK) | 0.5 | 5–10 | — |
8 | 69/F | Schnitzler | — | Continuous | — | — |